Navigation Links
Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohn's Disease
Date:10/8/2007

SAN DIEGO, Oct. 8 /PRNewswire/ -- Ocera Therapeutics, Inc., a privately-held biopharmaceutical company focused on the development and commercialization of proprietary compounds to treat gastrointestinal and liver diseases announced today that it has completed the patient enrollment of its Phase 3 study in fistulizing Crohn's disease. This pivotal, double-blind, placebo controlled study, FHAST1 (Fistula Healing with AST-120), has been designed to determine the efficacy and safety of oral AST-120 in 240 patients with Crohn's disease suffering from perianal fistulas. Initial data from the trial will be available in the first quarter of 2008.

"We are very pleased to have completed the enrollment in our FHAST1 pivotal trial evaluating AST-120 in a timely manner," stated Laurent Fischer, M.D., President and CEO of Ocera Therapeutics. "We would like to thank our investigators and patients in North America, Europe and Israel for their participation in the study."

Data from a double blind, placebo controlled Japanese study of AST-120 in fistulizing Crohn's disease sponsored by Kureha and presented at the Digestive Disease Week in May 2006 demonstrated that AST-120 significantly reduces draining fistulas compared to placebo.

"Up to one third of patients with Crohn's disease suffer from draining perianal fistulas, a chronic and debilitating condition that significantly affects their quality of life," said Professor Stephen Hanauer, M.D., Director of the Section of Gastroenterology and Nutrition at the University of Chicago and the Principal Investigator in the study. "Despite effective treatments, there is an unmet need for new and well-tolerated oral agents for patients with mild to moderate Crohn's disease who suffer from fistulas."

"We were pleased to participate in this Phase 3 trial evaluating the efficacy and safety of AST-120, a new oral treatment option, in fistulizing Crohn's disease," added Professor Simon Travis, M.D., Clinical Directo
'/>"/>

SOURCE Ocera Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
3. Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001 at American Association of Cancer Research Annual Meeting
4. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
5. Celsion Completes Enrollment in Phase I Liver Cancer Study
6. LANI completes Phase I in Japan and to commence Phase I in UK
7. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
11. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , Aug. 22, 2014 /PRNewswire/ - SQI ... that develops and commercializes proprietary technologies and products ... has entered into a Master Service Agreement to ... DNA-based pathogen detection assays. During the initial phase ... deliver an automated working prototype of one of ...
(Date:8/21/2014)... Nektar Therapeutics (NASDAQ: NKTR ... results from its Phase 3 pivotal clinical trial ... factor VIII (rFVIII) treatment for hemophilia A based ... primary endpoint in reducing annualized bleed rates (ABR) ... arm. Top-line results from the prospective, ...
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - The Canadian Epilepsy Alliance ... comic series designed to educate children about the most common ... Medikidz Explain Epilepsy comic series tells a fictional ... navigating middle school while living with epilepsy. ... there is still so much misinformation and lack of awareness ...
Breaking Medicine Technology:SQI Diagnostics Contracted to Automate Pathogen Detection Assays 2SQI Diagnostics Contracted to Automate Pathogen Detection Assays 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5Action Heroes Harness Powers to Educate Children About Epilepsy 2Action Heroes Harness Powers to Educate Children About Epilepsy 3
... 12, 2011 If you could learn that you have a ... and 75 percent of that chance could be altered by lifestyle ... of the nation,s leading online direct-to-consumer online lab test and health ... Your Number HealthScore as seen on The Biggest Loser ...
... 2011 Urologists for Patient Access to Care (UPAC) ... men should no longer receive prostate-specific antigen (PSA) blood ... major retrenchment in preventive health care." Dr. ... health care advocates to speak out to preserve prostate ...
Cached Medicine Technology:PersonaLabs and BioSignia Join to Offer Targeted Risk Assessment 2Cancer Detection Tool Saves Lives 2
(Date:8/22/2014)... NV (PRWEB) August 22, 2014 ... that is written by marketing experts for marketers to ... links has caught the attention of Shane Michaels, prompting ... with Internet marketing in any way knows that content ... in the industry,” reports Michaels. “But even though content ...
(Date:8/22/2014)... CA (PRWEB) August 22, 2014 Buying a ... an adult who is unsure about available coverage types by ... providing principal life insurance policy pricing to the public using ... use of this tool is free and is expected to ... available to the public throughout the U.S. The system is ...
(Date:8/22/2014)... Millennium Treatment Group has recently noticed an increase in ... drug use among teenagers. The treatment facility aims to help ... to minimize drug abuse. , America is currently seeing some ... history. According to the National Institute of Drug Abuse ... or older—or 9.2 percent of the population—had used an illicit ...
(Date:8/22/2014)... Norton HealthDay Reporter ... number of Americans on work disability chronically use powerful ... found that between 2007 and 2011, about 44 percent ... prescribed narcotic painkillers each year. And the percentage using ... to 23 percent in 2011. Experts said ...
(Date:8/22/2014)... -- Many Americans know little about how Ebola is transmitted ... in the United States, a new survey shows. About ... will be a major Ebola outbreak in the United States, ... member will get sick with the deadly virus in the ... Health poll. However, those opinions don,t match reality, the ...
Breaking Medicine News(10 mins):Health News:My Writers: Review Exposes Online Source for Quality Marketing Content 2Health News:Principal Life Insurance Policies Now Quoted for Adults at Insurance Website Online 2Health News:Millennium Treatment Group Sees Increase in Marijuana Use Among Youth 2Health News:Many U.S. Workers on Disability Use Narcotic Painkillers, Study Finds 2Health News:Many U.S. Workers on Disability Use Narcotic Painkillers, Study Finds 3Health News:Many U.S. Workers on Disability Use Narcotic Painkillers, Study Finds 4Health News:Many Americans Harbor Unfounded Fears About Ebola Outbreak: Survey 2
... turn out to be an important therapeutic target besides ... like uterus and prostate tissues. ,These new ... of estrogen in breast cancer and point the way ... disease. ,The new study was published this ...
... in on a transporter that actually quietens the body’s ... for potent and non-habit //forming pain killers and will ... ,Opioid peptides are natural pain relievers with receptors ... throughout the body, says Dr. Vadivel Ganapathy, chair of ...
... on the manner of T-cells enabling immunity and furthering chances ... go a long way in measuring the efficiency of AIDS ... ,Led by researchers at Beth Israel Deaconess Medical Center ... Institute of Allergy and Infectious Diseases (NIAID), part of the ...
... in public health for the rest of the country and ... Singh Barnala said today. // ,'Several medical colleges, ... to the success of the health care industry in the ... and the quality and commitment of our doctors had gained ...
... of Health and Family Welfare Anbumani Ramadoss Friday urged ... endorsing //soft drinks in the larger interest of public ... golden jubilee celebrations of the Central Food Laboratory (CFL) ... safety and regulatory mechanism to protect the vast population ...
... According to the researchers at the Harvard Medical School it ... lungs of chronically infected cystic fibrosis (CF) patients. // Pseudomonas ... disease in the CF patients says Joseph Mougous, lead author ... Science. ‘In the case of Pseudomonas aeruginosa, the host may ...
Cached Medicine News:Health News:Functional Differences In Estrogen Receptor Could Be A Therapeutic Target 2Health News:Functional Differences In Estrogen Receptor Could Be A Therapeutic Target 3Health News:Transporter offers reliable clues for safer pain medicine 2Health News:Transporter offers reliable clues for safer pain medicine 3Health News:Research on AIDS vaccine a wealth of information 2Health News:Research on AIDS vaccine a wealth of information 3Health News:Treatment of Bacterial Infection Paves the Way to Treat CF Infection 2
Ergotec Vetriretinal Instrument System. Reverse action jaws. 0.4 mm cupped tips....
Designed for peeling delicate epiretinal membrane in cases of premacular fibroplasia. Positive action closure. Barrel design with straight 20 gauge 40 gauge long shaft. 1 x 1.5 mm lightly serrated ja...
Triangular shaped tips. Marked for 5 mm and 10 mm tucks. Round knurled handle with polished finish....
Angled shafts with 9 mm scaled jaws. 1 mm teeth on one jaw fit into holes on the other jaw. Slide lock and serrated handle with polished finish. Left....
Medicine Products: